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Abstract: We often overlook banal events that take place under our 
eyes. Instead, they might represent inspiring sources for revolutionary 
scientific discoveries. Simple observations, such as those regarding 
the substantial immunity of the heart to cancer or the non-invasive 
behavior of plant tumors, are just iceberg tips hiding profound 
mechanistic causes that deserve deeper investigations. Several 
existing or unprecedented approaches aimed at improving both 
prevention and treatment of tumors are herein indicated on these 
bases. This viewpoint does not intend to give definitive answers, but 
rather to provide cues for discussion and motivations to engage 
unexplored and accessible strategies to fight cancer. 
Personalized vs. generalized medicine 
One of the most crucial questions for medicinal chemists while 
struggling to create innovative drugs is: “Are we hitting the right 
target?” This is especially puzzling when it comes to anticancer 
agents, due to the high heterogeneity displayed by different tumor 
types, organs involved, stage of the disease, mutations, etc. etc.  
A very large number of novel cancer targets have been so far 
identified. Many of these targets derive by an extremely complex 
analysis of mutations found in neoplastic cells. However, only a 
minor portion of them can be considered as driver gene mutations, 
which are those conferring a selective growth advantage, and 
they are difficult to spot among the numerous somatic mutations. 
Furthermore, the recurrence rates of driver mutations usually are 
quite low even within the same tumor type.[1] 
Most medicinal chemists (myself for sure!) have difficulties in 
understanding and handling the huge amount of information 
concerning all the significant recurring mutations for the 
development of new anticancer agents. Therefore, I would 
suggest a provocative approach, which is opposite to that deriving 
from “personalized” medicine and pharmacogenomics strategies. 
In fact, as medicinal chemists we can be confident that essential 
insight on these tactics may derive from current and future studies 
carried out by researchers working in other fields such as Medical 
and Biological Sciences. Anyway, will personalized medicine be 
affordable and accessible by the majority of cancer patients in the 
near future? Meanwhile, would not it be convenient to work also 
on some common-sense aspects and seek for more “generalized” 
tactics against malignant neoplastic diseases? 
Many scientific discoveries have so far derived from unexpected 
observations, although these were obviously followed by accurate 
scientific investigations. A classic example: bacteria do not grow 
in rotten culture media; this led to the discovery of antibiotics. It 
should be acknowledged that, since the discovery of penicillin, 
there have been continuous monitoring activities of bacterial 
mutations in order to produce new drugs that overcome antibiotic 
resistance. Nevertheless, the starting point of the β-lactam 
antibiotic era was a banal event. 
In anticancer therapy, unfortunately, a first accidental step similar 
to that of penicillin is still missing. As a matter of fact, we still have 
not found a class of drugs that efficiently kills all cancer cells with 
no or minimal toxicity to normal cells. We are already working on 
mutation analysis, occurrence of drug resistance, and 
personalized medicine, which are often efficient, but our 
anticancer therapeutic “column” has not been built on a solid 
“plinth”, as of yet. 
This viewpoint article is intended to indicate only some of the 
observations often reported also by nonscientists, in an attempt 
to build a reasonable picture that may inspire the scientific 
community to discover revolutionary antitumor agents or, else, to 
identify preventive measures and behaviors that can impact 
health policies. 
Heart is substantially immune to cancer 
Cancers are usually found in every bodily organ or system, 
although with various degrees of incidence rates. On the contrary, 
tumors of the heart are highly unusual and they generally start 
somewhere else in the body before spreading to the heart. Most 
(about 75%) of the very small portion of tumors that start in the 
heart are benign, whereas malignant primary heart tumors, known 
as cardiac sarcomas, are extremely rare.[2] 
Why are heart cancers so particularly exceptional as If they did 
not occur at all? And yet, heart is largely perfused and exposed 
to all carcinogens present in the blood flow, at least as much as 
most of the other organs in our body.  
 
Impaired cell division… ? 
Some could argue that cell division in cardiomyocytes is very 
limited (turnover of less than half of them during a normal life 
span).[3] Therefore, their inborn block of cell proliferation 
constitutes a protection against cancer. Nevertheless, neurons do 
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not undergo cell division either. Still, unfortunately, deadly 
cancers originating in the CNS are quite diffused among humans. 
Hence, this is not likely to be the real reason. 
 
…or tireless metabolic activity? 
Instead, this phenomenon may be related to metabolism. It is well-
known that the heart never rests (it’d better not!). It is constantly 
working and burning nutrients by oxidative metabolism, with no 
accumulation or deposit of energy reservoirs in the form of fat, 
which also results in a lower accumulation of lipophilic toxins. 
Conventional wisdom says that “it is usually preferable to drink 
continuously flowing spring water than standing water of a 
stagnant pond”. A continuous and efficient oxygen-consuming 
metabolism seems to be the key to this phenomenon. In fact, 
cardiomyocytes have a major limitation: they cannot contract in 
the absence of oxygen. Therefore, their indefatigable activity 
always occurs by means of aerobic mechanisms, as 
demonstrated by the high mitochondrial density present in these 
cells. Cardiomyocytes utilize also lactic acid to produce energy by 
means of its oxidation back to pyruvate. This is in sharp contrast 
with what happens in tumors, where cancer cells often adopt the 
glycolytic phenotype (Warburg effect) as a selective growth 
advantage feature, which is characterized by a predominant 
conversion of glucose to lactic acid. Actually, the metabolic profile 
of cancer cells within tumors is quite complex and represented by 
a highly heterogeneous situation where there are various 
metabolic sections collaborating with each other in order to 
guarantee cancer progression.[4] The metabolic plasticity of tumor 
cells reflects their ability to survive also in hostile environments, 
such as tumor hypoxia, and to adapt to the continuous 
environmental changes occurring during cancer progression. 
Nevertheless, it is clear that, while tumor tissues globally produce 
an excess of lactic acid in the surrounding tissues, which 
promotes tissue invasion, metastasis, angiogenesis and immune 
escape, the heart recycles lactate deriving from other 
compartments and utilize it as a fuel. 
Furthermore, the efficiency of the energy-producing oxidative 
process in the heart is much higher than that followed by most 
cancer cells. In fact, tumors need large amounts of glucose to 
survive and, therefore, their progression benefits from abundance 
of nutrients. It is not a case that there is a clear link between 
obesity and several types of cancer in humans, although the role 
of the adipose tissue in cancer progression is not limited to the 
supplying of extra-nutrients, but it also involves production of 
adipokines (TNF-α, IL-6, etc.), as well as promotion of 
inflammation and insulin resistance.[5] Right, insulin and insulin-
like growth factors (IGF1 and IGF2) are known to promote cancer 
development and progression, as well as drug resistance[6] and 
insulin resistance generally leads to increased levels of circulating 
insulin (hyperinsulinemia). This raises a personal speculative 
consideration: as opposed to heart cells, pancreatic cells are 
“soaked” in insulin; is this why pancreatic cancers (regardless 
their exocrine/endocrine origin) are so aggressive? 
Plants tumors do not metastasize 
Cancer, intended as an unrestrained proliferation of abnormal 
cells, affects both animals and plants. However, tumors cannot 
metastasize in plants, therefore the formation of metastases has 
to be related with circulation.  
Actually, the circulatory system is the means of transport of 
nutrients, waste products and CO2/O2 in both plants and animals. 
The main difference is that, differently from plants, animals do 
have cells circulating through the blood flow and the lymphatic 
system. Should this be the really significant difference? Maybe 
plant tumors do not metastasize because plant cells do not move 
around, contrary to what happens to some animal cells. 
If this is the real issue, I believe we should look more carefully at 
a possible role played by our circulating cells in the process of 
tumor dissemination. Of course, our immune system plays a 
fundamental role to counteract many pathologies, including 
infections and cancer. In fact, activation of T cell responses often 
results in the control of cancer progression, because these 
lymphocytes can spot tumor antigens and activate their effector 
programs even within neoplastic tissues. This aspect constitutes 
the basis for success of anticancer immunotherapy against a 
considerable number of cancer types. 
On the other hand, there is growing evidence that some specific 
classes of white blood cells, such as macrophages and 
neutrophils, are involved in a kind of “betrayal”, which make them 
“accomplices” in cancer malignancy. 
 
Macrophages 
Macrophages constitute a first line of defense of our immune 
system and are devoted to phagocyte cells that are considered to 
be a threat to our body. However, in cancer the normal function 
of macrophages is often found to be disrupted, so that tumor-
associated macrophages (TAMs) can be either tumor killing (M1) 
or tumor promoting (M2). Thus, the M2-type of TAM starts to 
promote tumor growth and invasion. This is thought to be due (at 
least in part) to the chronic inflammation present in the tumor 
microenvironment (TME) and to the consequent release of 
inflammatory factors. TAMs were found to directly interact with 
cancer cells and to protect them from radio- and chemotherapies 
by means of their innate tissue repair response. Furthermore, they 
are able to promote angiogenesis and immunosuppression when 
within the TME.[7]  
 
Neutrophils 
Neutrophils constitute the most abundant immune cells in humans, 
representing 50–70% of all leukocytes. These cells have been 
considered for quite a long time as an unimportant component of 
TME, although more recently there is evidence that they do not 
really assume a “neutral” behavior in cancer.[8] Actually, there is 
an ongoing discussion about how and when these cells display 
pro-tumor or anti-tumor properties, since they have been reported 
to either oppose or potentiate the development of neoplastic 
diseases. More recent investigations seem to attribute an 
important role to tumor-associated neutrophils (TANs) in tumor 
progression.[7] In fact, tumors exploit several pathways to disrupt 
normal neutrophil activities and to make them accomplices in the 
progression of the disease. 
The mechanism by which neutrophils promote tumor initiation, 
growth and metastasis is not completely clear. However, it is 
known that neutropenia induced by chemotherapy is often 
associated with improved survival in patients with various types of 
cancer.[9]  
There is clinical evidence supporting the count of neutrophils and, 
in particular, the neutrophil to lymphocyte ratios (NLRs), as 
biomarkers for the prediction of cancer recurrence or progression. 
In fact, a reduction of these parameters during therapy or after 
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surgery is generally an indication of a good response, whereas a 
rise in their value is associated to a poor prognosis.[10]  
It is now well-established that inflammation plays a key role in 
cancer and neutrophils can be considered as a crucial link 
between the inflammatory process and malignant neoplasms. 
However, the way by which neutrophils promote tumor 
development is not entirely understood. For sure, not all 
neutrophils are equal, but they are subject to phenotypic changes 
that are sensitive to the control operated by tumor-derived factors, 
which enhance the immunosuppressive properties of neutrophils. 
Neutrophils are also known to be promoters of angiogenesis, 
which contributes to tumor growth and cancer cell extravasation 
into the bloodstream. Furthermore, neutrophil extracellular traps 
(NETs), which are generally employed to capture and eradicate 
invading microbes, are also used to recruit circulating cancer cells 
and guide them into distant organs, thus promoting the formation 
of metastases.[11] Actually, neutrophils were found to concentrate 
in distant organs earlier than cancer cells start colonizing those 
compartments, thus generating the so-called “premetastatic 
niche”. This preliminary accumulation was found to be promoted 
by tumor-derived factors.[12] Currently, there is an important need 
to develop reliable models in order to finally establish the timing 
and mechanisms by which neutrophils support cancer 
progression, so that we may find suitable targets to be exploited 
for therapeutic interventions. Since these immune cells do not live 
long in ex vivo cultures, their behavior should be necessarily 
studied in vivo. 
Dwarfism, age, diabetes and cancer risk 
A community of people in Ecuador displaying a Laron-type 
dwarfism was observed for more than 20 years and they turned 
out to be substantially immune to cancer and diabetes. These 
individuals carry mutations in the growth hormone receptor (GHR), 
which leads to an insensitivity to growth hormone (GH), with 
consequent short stature. This syndrome also causes a 
deficiency of IGF1 and a concomitant increased sensitivity to 
insulin (thus no diabetes!).[13] On the contrary, it was 
demonstrated, that height is associated with increased risk of 
cancer and cancer death. This phenomenon does not seem to be 
related to the higher number of cells present in taller people. It 
rather depends on genetic and hormonal factors, in particular, on 
the GH/IGF1 axis, which is stimulated also by nutrition during 
childhood and adolescence.[14] Should we then correlate the age-
dependent life-long decrease of GH and IGF1 levels with the fact 
that certain types of cancer are more aggressive in younger than 
older patients? 
On the other hand, subjects with type-2 diabetes (reduced insulin 
sensitivity) present a remarkable increase in the pancreatic 
cancer risk.[15] Furthermore, metformin, an anti-diabetic drug, 
displayed a significant anticancer activity in diabetics,[16] although 
it is still not clear if its efficacy against tumors depends on its 
action on the electron transport chain (ETC) of cancer cells or 
rather on the reduction of systemic insulin and glucose levels 
caused by this drug.  
Possible therapeutic/preventive strategies 
Patients should always be warned against fraudulent or ignorant 
medical practices promoted by charlatans with no scientific 
evidence supporting their efficacy and safety. Nevertheless, 
currently available therapies, which are often curative, in some 
cases would benefit from the assistance of other types of 
interventions. I would skip the discussion of most obvious 
preventive recommendations, such as “do not smoke”, “drink less 
alcohol” and “protect your skin from sun exposure”. However, 
there are other suggestions for cancer prevention/therapy that are 
related to some of the observations described in the previous 
sections. 
 
“Follow your heart”: physical activity, proper diet/caloric 
restriction mimetics, lactate-lowering anti-glycolytic agents. 
Obesity (remember: heart has no fat deposits) was found to be 
associated to an increased risk of cancer affecting different sites, 
such as colon, esophagus, stomach, kidney, breast, uterus, liver, 
gallbladder, pancreas, prostate, ovary, thyroid, meninges 
(meningioma) and plasma cells (multiple myeloma).[17] Therefore, 
anti-obesity interventions would be valuable preventive strategies, 
although they need to be controlled and well-balanced, otherwise 
an extreme weight loss may cause cachexia or neutropenia. 
Some of the measures aimed at reducing excess weight are 
discussed below.  
Non-strenuous physical activity was found to be related to lower 
risks of several types of cancer, with the single exception of 
malignant melanoma (probably due to the higher non-protected 
exposure to sunlight related to outdoor leisure activities). 
Therefore, sedentary adults should be educated by health care 
professionals about this fundamental instrument of prevention 
and cure.[18]  
Over the past few millennia, health benefits deriving from periodic 
fasts dictated by the most diffused religions on earth might have 
constituted an evolutionary advantage, since they are now being 
recognized as therapeutic and preventative interventions against 
several afflictions. They should be reconsidered even on the basis 
of scientifically rational concepts and properly modulated in 
accordance with specific needs. So low-calorie diets, caloric 
restriction mimics and/or periodic fasting are effective ways to 
prevent cancer or to improve the efficacy of anticancer 
therapies.[19] For example, short-term starvation proved to 
sensitize various cancer cell types to chemotherapy in both in vitro 
and in vivo models. This intervention promoted apoptosis and an 
anti-Warburg effect, consisting in an increased oxygen 
consumption and a reduced glycolysis (remember: heart is 
constantly active by means of an oxidative metabolism).[20] There 
is some evidence suggesting that consumption of some food 
stimulating the GH/IGF1 axis should be limited. As mentioned 
above, GH, IGF1, and insulin are now being considered as key 
mediators of tumor development, and scientists are trying to figure 
out how to use this information to develop therapeutic strategies. 
For example, insulin-lowering agents, such as metformin[16] or 
diazoxide[21] have already shown some promising preclinical 
results against neoplastic diseases. Meanwhile, some foods were 
also identified as strong promoters of the GH/IGF1 pathway, such 
as milk and dairy products, whose consumption was positively 
associated with an increased risk of cancer by means of an 
increase of the levels of IGF1.[22] The impact of a high protein 
intake, especially milk proteins, on the stimulation of growth is 
made evident by the dramatic increase in the average height of 
some populations in Europe over the past century. For example, 
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the tallest people over these years are the Dutch, whose average 
heights is 182 cm, starting from a value of only 168 cm one 
century before.[23] The Dutch are amongst the main consumers of 
milk and dairy products in the world (I have to admit milk is so 
good in the Netherlands!). Dairy product intake especially during 
childhood and puberty might be the cause of such a stunning 
change because of the potent stimulation of the GH/IGF1 pathway. 
This type of feeding would not be so essential in adults. It is still 
not clear if this population present higher risks of developing 
tumors (taller people do show greater risk, though[14]), but all 
these data would indicate that a reduction in the intake of milk and 
dairy products during maturity may be beneficial. A few years ago 
a 4-fold increase in cancer death risk was found to be associated 
to individuals aged 50–65 reporting high protein intake, thus 
suggesting dietary intervention with a reduced protein intake to 
prevent cancer.[24] Furthermore, pharmacological attempts to 
disrupt the IGF1 action were carried out with somatostatin 
analogues, since these drugs had already been approved for the 
treatment of acromegaly. Similarly, an antagonist of the GH 
receptor, pegvisomant (another drug used for treating 
acromegaly) is currently being considered as a perspective 
anticancer agent, since it is able to significantly reduce the plasma 
levels of IGF1.[25]  
Going back to lactate: the heart efficiently burns it in an oxidative 
way to produce energy and CO2. On the contrary, tumors produce 
massive amounts of lactic acid, which promotes immune-escape, 
resistance, angiogenesis, tumor invasion and metastasis 
formation.[26] Therefore, lactate should now be considered both as 
a diagnostic biomarker and as a therapeutic target. 
Early diagnosis of tumors still constitutes one of the major 
challenges in oncology. Unfortunately, the most reliable 
techniques, such as PET/CT scan and magnetic resonance 
imaging (MRI), cannot be utilized for high-throughput screening of 
a large population. Even the low-dose computed tomography 
(LDCT) is expensive and presents a high rate of false-positive, 
together with the exposure to potentially harmful radiation doses. 
More recently, the use of our best friends (or doctors?), the dogs, 
for the early diagnosis of cancer is emerging as a very promising 
preventive strategy. This approach is supported by the fact that 
dogs have a very sensitive olfaction, so they detect the altered 
production of metabolites in human cancer. So far, scientists have 
focused their attention to a specific class of metabolites, called 
Volatile Organic Compounds (VOCs), such as some types of 
aliphatic aldehydes, whose production is enhanced in cancer. 
This has led to development of analytical techniques and sensors 
(“electronic noses”) that are able to detect these substances even 
in the absence of a canine companion.[27] However, the profile of 
VOCs varies considerably in different tumor types, whereas dogs 
do not seem to be influenced by the type of cancer they were 
trained for. It was later hypothesized that cancer cells have a 
unique odor pattern, regardless the different types of cancer.[28] 
Could this common smell derive from lactic acid? This compound 
is not as volatile as VOCs (it does smell, though!), but it already 
proved to be a potent mosquito attractant. Detection of lactate has 
been so far limited only to a few medical practices, mainly 
involving the monitor of sport activities in athletes. Therefore, we 
now have the technology (it can be easily improved for ad hoc 
applications) to screen large portions of population for abnormal 
production of lactate. Although the utility of this potential 
biomarker still needs to be fully demonstrated, it may be used for 
a first-line high-throughput screening of cancer, before submitting 
patients to more specific CT or MRI scans for a confirmation of 
the diagnosis. Detection of lactate can be carried out in a series 
of specimens, depending on the sensitivity required and on the 
location of the tumor. While a quantification of this metabolite in 
the blood may be poorly sensitive and subject to a large number 
of interferences (in this case, serum levels of lactate-producing 
enzyme LDH-A are considered as a more reliable prognostic 
marker[29]), an analysis of lactic acid in exhaled breath may be 
used for an advance warning of lung cancer. Similarly, stool 
(colorectal), urine (bladder, kidney), saliva (oral), etc. may be 
utilized for early detection of other types of cancer. Of course, the 
use of lactic acid as a biomarker will result in many false positive 
cases, because overproduction of lactate may be due to several 
other concomitant conditions, such as strenuous physical 
exercise, fatigue, infections etc. Nevertheless, I believe it is worth 
a shot and trials for its validation should be implemented as soon 
as possible. 
A particular attention should be dedicated to the clinical use of 
lactate in parenteral formulations, due to its above-mentioned 
activities supporting cancer progression. There are solutions such 
as, for example, Ringer’s lactate or Hartmann's solution, which 
are often utilized after surgery or losses of body fluid. It would 
probably be advisable to replace them with analogous lactate-free 
solutions, especially in cancer patients, since there might be a 
non-negligible risk of boosting diffusion of cancer cells in the 
whole body and formation of metastases. 
From a therapeutic point of view, any intervention aimed at 
interfering with the peculiar metabolism of tumors characterized 
by the overproduction of lactic acid should be considered as a 
promising approach for the development of new anti-glycolytic 
agents against cancer. This is a rapidly emerging field where 
medicinal chemists should definitely concentrate their efforts, 
because the clinical development of anti-glycolytic drugs is not 
adequate, as of yet. In fact, only a very limited number of 
candidate drugs that modulate cancer glycolysis have entered 
clinical trials. Some of the most representative examples are: AG-
348, a pyruvate kinase (PK) activator; AZD3965, a 
monocarboxylate transporter 1 (MCT1) inhibitor; dichloroacetate 
(DCA), a pyruvate dehydrogenase kinase (PDK) inhibitor; AT-101 
(gossypol-acetate complex) an inhibitor of lactate dehydrogenase 
(LDH) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH); 2-deoxyglucose (2-DG) and 3-bromopyruvate (3BP), 
inhibitors of various key glycolysis enzymes; lonidamine, a 
hexokinase (HK) and MCT1 inhibitor; silybin, a natural product 
that blocks glucose transporters (GLUTs),[30] To the best of my 
knowledge, none of them has yet received final approval for 
clinical use. Therefore, a more intensive effort in this strategy is 
urgently needed. 
 
“Real eyes realize real lies”: so neutralize non-neutral 
neutrophils! 
Wise men say: “Beware of your friends more than your sworn 
foes!”. Our immune cells (remember: plants do not have them) are 
generally “friends”, which occasionally might even turn into 
enemies. Therefore, any successful therapeutic intervention 
should: a) fortify the “good cops”; b) spot the “betrayers” and 
destroy them. 
Anticancer immunotherapies that increase the capacity of 
endogenous T cells to eliminate malignant cells have proved 
therapeutic efficacy in a wide panel of human cancers. In 
particular, there are tumor-specific antigens, called neoantigens, 
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whose recognition is now considered as a foremost cause in the 
positive outcome of immunotherapies in the clinic. So, in the 
future it will be essential to develop immunotherapies that 
selectively enhance neoantigen-specific T cell reactivity, in order 
to obtain high specificity and safety.[31] In parallel, there are other 
“trivial” options that might be more easily applied. For example, a 
certain degree of stimulation of anticancer T cell responses can 
also be obtained by some chemotherapeutic agents (for example, 
doxorubicin). In this frame, caloric restriction was recently 
demonstrated to improve this anticancer immune response. In 
fact, the effect of a fasting-mimicking diet or caloric restriction 
mimetics (such as hydroxycitrate) increased the number of “good” 
tumor infiltrating CD8+ cytotoxic T cells, leading to an 
improvement of the therapeutic outcome.[32]  
On the other hand, as mentioned above, some immune cells are 
now being considered as partners in tumor progression. The 
recently identified role of some macrophages as “corrupted 
policemen” has made them as an appealable target for anticancer 
therapies, leading in several cases to the reduction of tumor 
growth and of metastatic spread, as well as to synergistic effects 
when combined with antiangiogenic and chemotherapeutic 
agents.[33] For example, trabectedin, a chemotherapeutic agent 
that kills monocytes/macrophages, demonstrated therapeutic 
efficacy against tumors in mouse models.[34] The main problem in 
this approach is that a pan-macrophage treatment might produce 
important side effects, since it targets all macrophages. So more 
refined therapies that only target TAMs are urgently needed. 
As for neutrophils, most of the molecules under current 
investigation are clinically approved drugs, whose indications 
generally concern inflammatory and autoimmune diseases. For 
example, zileuton, an approved drug for the treatment of 
inflammatory asthma, is an inhibitor of arachidonate 5-
lipoxygenase (Alox5), an enzyme that generates leukotrienes 
(LTs). This drug also proved to reduce the formation of lung 
metastases in a breast cancer model and this effect seems to be 
due to the block of the pro-metastatic activity of neutrophils which 
depends on the LT/Alox5-axis.[12] Moreover, it is known that 
neutrophil mobilization from the bone marrow is regulated by a 
signaling pathway via the C‑X‑C chemokine receptors (CXCRs). 
Thus, an antagonist of CXCR1 and CXCR2, reparixin,[35] is 
currently being employed in ongoing clinical trials in cancer 
patients,[36] since it seems to counteract the formation of 
metastases by reducing neutrophil counts, inflammatory 
biomarkers and, allegedly, also the contribution of cancer stem 
cells to tumor dissemination. 
A separate reflection should be dedicated to the use of 
Granulocyte Colony Stimulating Factor (G-CSF) and Granulocyte 
Macrophage Colony Stimulating Factor (GM‑CSF). These factors 
are often administered to cancer patients to counteract 
chemotherapy-induced neutropenia, which might lead to severe 
infections. Unfortunately, recent studies demonstrated that they 
induce a pro-tumorigenic phenotype of neutrophils and support 
metastasis formation.[37] Another study showed that neutralization 
of G-CSF or interleukin-17 reduces the formation of lung and 
lymph node metastases in a mouse model of breast cancer by 
preventing neutrophil accumulation and their T-cell-suppressive 
phenotype.[38] A similar phenomenon was also observed in 
macrophages, because GM-CSF may act in pro-tumoral fashion 
by stimulating TAMs[39] and treatment with a brain-penetrant 
inhibitor of CSF-1 receptor (BLZ945) proved to be effective in a 
glioma xenograft model.[40] Similarly, TAM-depleting effects 
obtained by administration of a monoclonal antibody that blocks 
the activity of macrophage colony-stimulating factor 1 (CSF-1) 
produced marked clinical benefits, when combined with standard-
of-care treatments in patients affected by various types of solid 
tumors.[41] In any case, a particular caution should be taken before 
administering G-CSF to cancer patients and the risk-benefit ratio 
should be more precisely assessed by a careful analysis of large 
populations. In addition, there is an urgent need for more selective 
therapeutic interventions which are able to prevent neutropenia-
induced infections without stimulating the neutrophil or 
macrophage pro-metastatic character. 
Finally, it is now widely accepted that anti-inflammatory agents 
can be profitably used together with standard anti-tumor 
treatments. In fact, a reduction of systemic inflammation caused 
by cancer, once considered only as a palliative care for symptom 
control, remarkably improves not only the quality of life, but also 
the survival rate in oncologic patients.[42] The good news is that 
some classical non-steroidal anti-inflammatory drugs (NSAIDs), 
such as naproxen, ibuprofen and oxaprozin, were found to reduce 
neutrophil migration by means of a mechanism that is 
independent of COX inhibition and PGE2 release.[43] The direct 
effects of these arylpropionic NSAIDs on neutrophil behavior 
should inspire extensive studies aimed at the discovery of new 
and more specific anti-cancer drugs targeting this type of immune 
cells. 
Summary and outlook 
“The History of the World Based on Banalities” is the title of a 
theatre show, but it may be as well used to explain the sense of 
this personal viewpoint, where trivial observations are proposed 
to stimulate the implementation of new strategies to tackle cancer. 
Among the numerous possible points of intervention deriving from 
the above-mentioned observations, some of them are 
summarized in the following list of over-simplified suggestions, to 
be considered in combination with standard-of-care therapies and 
under the supervision of healthcare professionals: 
1) Promotion of non-strenuous physical activity as a regulation 
in defense of public health. 
2) Reduction of caloric intake (diet, fasting, caloric restriction 
mimetics). 
3) Anti-IGF1/GH interventions (somatostatin analogues, 
pegvisomant, diet, reduced protein intake). 
4) Detection of lactate as a biomarker (dogs, sensors). 
5) Safety check of clinically used parenteral solutions 
containing lactate. 
6) Development of anti-glycolytic drugs. 
7) Anti-cancer immune-fortification (immunotherapy, fasting-
mimicking diet, caloric restriction mimetics). 
8) Development of anti-macrophage agents (trabectedin). 
9) Development of anti-neutrophil agents (reparixin). 
10) Safety check of Colony Stimulating Factors (G/GM-CSF) 
and of their risk-benefit ratio. 
11) Higher employment of anti-inflammatory (anti-TAMs/TANs) 
drugs in cancer treatment protocols. 
Of course, these are just hints for discussion, which may not 
necessarily encounter a universal consent in the scientific 
community. Anyway, cancer is such a complex disease, maybe it 
is even a complex collection of different diseases, whose 
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treatment requires a wide panel of interventions, which cannot be 
limited to a single therapeutic protocol. So, in order to reduce the 
complexity of the treatment options and, at the same time, to 
increase the chance of their implementation, a series of “easy” 
deductions and common-sense approaches are herein proposed. 
Let’s fly low for a while. We may be surprised by what we can see 
from closer distances. 
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